Frazier Life Sciences Management Portfolio holdings
Frazier Life Sciences is a biotech investment firm that backs companies developing new drugs, from their formation through to public markets. It started operations in 2022 and is owned mainly by Jamie Topper and Patrick Heron. Its Public Fund invests mainly in listed drug and biotech companies, with up to a fifth of its portfolio available for financings of private ones, while the firm's other funds mostly back private companies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines
PBLS
|
+$53.1M |
| 2 |
Allogene Therapeutics
ALLO
|
+$41M |
| 3 |
NewAmsterdam Pharma
NAMS
|
+$37.7M |
| 4 |
Achieve Life Sciences
QUIT
|
+$36.3M |
| 5 |
Kailera Therapeutics
KLRA
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$133M |
| 2 |
KalVista Pharmaceuticals
KALV
|
+$100M |
| 3 |
Revolution Medicines
RVMD
|
+$65.7M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$42.5M |
| 5 |
Trevi Therapeutics
TRVI
|
+$1.45K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.77% |
| 2 | Miscellaneous | 0.23% |
Similar funds
Frazier Life Sciences Management's Q2 2026 Portfolio in Review
As of Q2 2026, Frazier Life Sciences Management held 44 positions worth $4.59B, up 18% from $3.89B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Frazier Life Sciences Management's Q2 2026 filing shows 6 new, 8 increased, 2 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines: 1,920,805 shares worth $52.6M. The largest sale was BridgeBio Pharma, an estimated $133M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2026 buy was Parabilis Medicines: 1,920,805 shares worth $52.6M.
- Frazier Life Sciences Management added most to Allogene Therapeutics in Q2 2026, an estimated $41M increase.
- Frazier Life Sciences Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $133M.
- Frazier Life Sciences Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $100M.
- Frazier Life Sciences Management's ten largest holdings make up 74% of its $4.59B portfolio in Q2 2026.
- Frazier Life Sciences Management opened 6 new positions and closed 3 in Q2 2026.
- Frazier Life Sciences Management's portfolio value rose 18% quarter-over-quarter to $4.59B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.